The KRAS p.G12C mutations harbor more aggressive clinicopathologic and genomic features than other KRAS-mutant tumors and were associated with worse DFS after the complete resection of stage I–III lung adenocarcinoma, a correlation that was not investigated in our cohort [36]. Here, KRAS is linked to lung adenocarcinoma.